Skip to main content
. 2019 Nov 15;11(11):1021–1030. doi: 10.4251/wjgo.v11.i11.1021

Figure 1.

Figure 1

Kaplan-Meier estimates of progression-free survival and overall survival, according to treatment groups. A: Shows progression-free survival; median was 2.0 mo in the group received capecitabine, 2.7 mo in the group received S-1; B: Shows overall survival; the median was 4.3 mo in the capecitabine group and 5.0 mo in the S-1 group.